Cosmo Pharmaceuticals N.V. (SWX:COPN)

Market Cap	880.83M
Revenue (ttm)	250.29M
Net Income (ttm)	125.00M
Shares Out	16.02M
EPS (ttm)	7.61
PE Ratio	7.22
Forward PE	9.26
Dividend	1.96 (3.57%)
Ex-Dividend Date	n/a

Volume	10,221
Average Volume	24,070
Open	54.00
Previous Close	55.00
Day's Range	54.00 - 55.20
52-Week Range	52.60 - 80.60
Beta	1.30
RSI	35.52
Earnings Date	Mar 6, 2025

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1997
• Employees: 322
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: COPN

Financial Performance

Financial numbers in EUR